This recent story from has captured global attention. At its centre is Rosie, a dog diagnosed with an incurable cancer, and her owner, tech entrepreneur Paul Conyngham, who worked with researchers across the University of New South Wales (UNSW) and The University of Queensland to design and deliver a highly personalised mRNA-based cancer treatment.

The story has quickly moved beyond research circles, attracting media coverage, including a feature on the Today Show with Prof. Palli Thordarson, Director of the UNSW RNA Institute. While headlines have focused on the novelty of an AI-designed cancer vaccine, this highly individualised case, developed outside a clinical trial setting, offers a glimpse into how advances in RNA, genomics and computation are beginning to translate into real-world applications.

This work brought together capabilities supported through the National Collaborative Research Infrastructure Strategy (NCRIS), including Therapeutic Innovation Australia (TIA) and Bioplatforms Australia. These providers enable open access to the facilities and expertise required to deliver new therapeutic approaches.

The genomic sequencing and mutation analysis were performed at the UNSW Ramaciotti Centre for Genomics, a facility supported by Bioplatforms Australia, which provided the critical data that made the personalised vaccine possible.

The mRNA vaccine used in Rosie’s treatment was produced at the UNSW RNA Institute, a facility supported by TIA. This demonstrates the growing ability to connect key elements of modern therapeutic development, from genomic profiling and computational design through to RNA formulation and delivery.

There are still many scientific questions to answer. However, the significant reduction in Rosie’s tumours points to what can be achieved when these capabilities are applied in a coordinated way, and when researchers have access to them within Australia.

As RNA technologies continue to develop, the ability to design and produce personalised therapeutics will increasingly depend on access to specialised facilities, skilled expertise and strong collaborative networks.

Rosie’s story is still evolving, but it offers an early indication of what may become possible as these capabilities continue to mature and researchers leverage genomics and RNA-based technologies towards personalised immunotherapies and vaccines.